There are several efficacious systemic therapy options for metastatic PCa at different stages of the disease (e.g., ADT, second-generation androgen receptor inhibitors, chemotherapy, poly-ADP ribose polymerase [PARP] inhibitors, and lutetium-177-PSMA-617 [106, 107]), some of which have only been introduced in the past few years, and is also a field of intense research [108]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.